Erythropoiesis-stimulating agents in patients with chronic kidney disease

Mario Eandi

DOI: https://doi.org/10.7175/rhc.v3i2.194

Abstract

Anemia is a frequent complication of chronic kidney disease (CKD) due to the inability of the kidneys to release sufficient erythropoietin to regulate the production of red blood cells. Administration of erythropoiesis-stimulating agents (ESAs) is highly effective in correcting anemia of CKD. The ESAs currently approved in Italy are epoetin alfa, epoetin beta, epoetin theta, darbepoetin alfa, CERA and biosimilars epoetin alfa and epoetin zeta. All the ESAs are effective in correcting renal anemia and increasing hemoglobin levels, but the choice of which to use should also take into account their pharmacokinetics and pharmacodynamics, their administration route, and economic issues. However, regarding the optimal use of ESAs an issue that remains controversial is the most appropriate dose conversion between epoetin alfa and darbepoetin alfa. In fact clinical experience demonstrates that the dose relationship between epoetin alfa and darbepoetin alfa is non proportional across the dosing spectrum. In this review is presented an update on the latest available evidence in the treatment of anemia in CKD patients, with particular reference to the definition of the correct conversion ratio EPO:DARB.

Keywords

Chronic kidney disease; Anemia; Erythropoiesis-stimulating agents; Dose conversion; Darbepoetin alfa

Full Text

HTML PDF

References

  • Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989; 35: 134-48
  • Eschbach JW, Varma A, Stivelman JC. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia? Nephrol Dial Transplant 2002; 17 (Suppl 5): 2-7
  • Urabe A, Takaku F, Mizoguchi H, et al. Effect of recombinant human erythropoietin on the anemia of chronic renal failure. Int J Cell Cloning 1988; 6: 179-91
  • Powe NR, Griffiths RI, Greer JW, et al. Early dosing practices and effectiveness of recombinant human erythropoietin. Kidney Int 1993; 43: 1125-33
  • Frenken LA, Verberckmoes R, Michielsen P, et al. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients. Nephrol Dial Transplant 1989; 4: 782-6
  • Schaefer RM, Schaefer L, Heidland A. Recombinant human erythropoietin for anaemia associated with chronic renal failure in predialysis patients. Przegl Lek 1992; 49: 41-2
  • Albertazzi A, Di LL, Daniele F, et al. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study. Int J Artif Organs 1998; 21: 12-8
  • Horl WH. A need for an individualized approach to end-stage renal disease patients. Nephrol Dial Transplant 2002; 17 (Suppl 6): 17-21
  • Macdougall IC. Erythropoietin and renal failure. Curr Hematol Rep 2003; 2: 459-64
  • Germain M, Ram CV, Bhaduri S, et al. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Nephrol Dial Transplant 2005; 20: 2146-52
  • Locatelli F, Del Vecchio L. Erytropoiesis-stimulating agents in renal medicine. Oncologist 2011; 16 (Suppl 3): 19-24
  • Triolo G; Italian Society of Nephrology. Guidelines for the treatment of anemia in chronic renal failure. G Ital Nefrol 2003; 20 (Suppl 24): S61-82
  • National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471-530
  • Locatelli F, Covic A, Eckardt A, et al. on the behalf of the ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24: 348-54
  • Agarwal AK. Darbepoetin alfa for anemia in chronic kidney disease. Expert Rev Clin Pharmacol 2008; 1: 369-79
  • Canavese C, Strippoli GFM, Bonomini M et al. Haemoglobin targets for chronic kidney disease: guideline from the Italian Society of Nephrology. G Ital Nefrol 2007; 24 (Suppl 37): 99-106
  • Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int Suppl 2009; 113: S1-130
  • Nurko S. Anemia in chronic kidney disease: causes, diagnosis, treatment. Cleve Clin J Med 2006; 73: 289-97
  • Report Annuale Registro Italiano Dialisi e Trapianto (RIDT), 2009. Disponibile su http://www.sin-ridt.org/Italia/Report2009/REPORT%20RIDT%202009.pdf (ultima consultazione novembre 2011)
  • Neri L, Viglino G, Barbieri S, et al. Epidemiologia della Insufficienza Renale Cronica (IRC). Bollettino Epidemiologico Asl 18, 2004. Disponibile su http://www.epicentro.iss.it/territorio/bollettinobra2004.pdf (ultima consultazione novembre 2011)
  • McFarlane SI, Chen SC, Whaley-Connell AT, et al. Prevalence and Associations of Anemia of
  • CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. American J Kidney Dis 2008, 51 (Suppl 2): S46-55
  • Popolazione residente al 1 Gennaio 2011 per età, sesso e stato civile. Disponibile su http://demo.istat.it/pop2011/index.html (ultima consultazione novembre 2011)
  • Fishbane S. The role of erythropoiesis-stimulating agents in the treatment of anemia. Am J Manag Care 2010; 16: S67-S73
  • Villa G. Erythropoiesis-stimulating agents: from the origins to new challenges. G Ital Nefrol 2010; 27 (Suppl 52): S38-46
  • AIFA. Elenco farmaci autorizzati. Disponibile su http://farmaco.agenziafarmaco.it/index.php (ultima consultazione novembre 2011)
  • Determinazione AIFA - Aggiornamento del Piano terapeutico AIFA per prescrizione SSN di Eritropoietine (ex Nota 12). Disponibile su http://www.agenziafarmaco.gov.it/sites/default/files/2010-07-29_determina_aggiornamento_template_nota_12_g.u._75_del_31-03-2009.pdf (ultima consultazione novembre 2011)
  • Locatelli F, Aljama P, Barani P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(suppl 2): 1-47
  • National Kidney Foundation. K/DOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006; 47(suppl 3): 16-85
  • Locatelli F, Aljama P, Canaud B, et al.; and On behalf of the Anaemia Working Group of
  • European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) Study. Nephrol Dial Transplant 2010; 25: 2846-50
  • Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 23-33
  • Locatelli F, Canaud B, Giacardy F, et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003; 18: 362-9
  • Brunkhorst R, Bommer J, Braun J, et al. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 2004; 19: 1224-30
  • Shalansky K, Jastrzebski J. Complete switch to darbepoetin in a hemodialysis unit. Clin Nephrol 2005; 64: 55-63
  • Scott SD. Dose conversion from recombinant human erytrhopoietin to darbepoetin alfa: recommendations from clinical studies. Pharmacotherapy 2003; 22: 160-5
  • Roger SD, Cooper B. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? Nephrology (Carlton) 2004; 9: 223-8
  • Bonafont X, Bock A, Carte D, et al. A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis. NDT Plus 2009; 2: 347-53
  • Eandi M, Giotta N, Biamino E, et al. Analisi costo/efficacia di darbepoetina dopo switch da epoetina-beta nei pazienti in emodialisi: studio retrospettivo monocentrico italiano. Farmeconomia e Percorsi Terapeutici 2006; 7: 45-62
  • Giotta N, Biamino E, Eandi M. Costo ed efficacia clinica a lungo termine di darbepotin-alfa nei pazienti in emodialisi: risultati degli ultimi 12 mesi di uno studio retrospettivo monocentrico italiano della durata di 24 mesi. Farmeconomia e Percorsi Terapeutici 2007; 8: 61-9
  • Tolman C, Richardson D, Bartlett C, et al. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol 2005; 16: 1463-70
  • Raymond CB, Wazny LD, Vercaigne LM, et al. Conversion from epoetin alfa to darbepoetin alfa within the Manitoba Renal Program: evaluation of dose ratios. CANNT J 2008; 18: 39-43
  • Bock HA, Hirt-Minkowski P, Brünisholz M, et al.; Swiss EFIXNES trial investigators. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta. Nephrol Dial Transplant 2008; 23: 301-8
  • Horowitz J, Agarwal A, Huang F, et al. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease. J Manag Care Pharm 2009; 15: 741-50
  • Sharma A, Yee J, Gandra SR, et al. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population. Curr Med Res Opin 2010; 26: 2679-87

Statistics

Abstract: 991 views
HTML: 1583 views
PDF: 1671 views

Refbacks

  • There are currently no refbacks.




© SEEd srl